Article
Radiology, Nuclear Medicine & Medical Imaging
Ricardo Donners, Nina Tunariu, Holly Tovey, Emma Hall, Sue Chua, Gary Cook, Yong Du, Matthew D. Blackledge, Christopher C. Parker, Dow-Mu Koh
Summary: The study aimed to investigate whether baseline 18F-sodium fluoride (NaF) and 18F-choline PET activity is associated with the response of metastatic castration-resistant prostate cancer (mCRPC) bone metastases to radium-223 treatment. The results showed a significant correlation between the baseline 18F-NaF PET SUVmax value and treatment response, while there was no significant association between the 18F-choline PET SUVmax value and treatment response.
EUROPEAN RADIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Mari I. Suominen, Matias Knuuttila, Christoph A. Schatz, Andreas Schlicker, Jukka Vaaraniemi, Birgitta Sjoholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Kakonen, Arne Scholz
Summary: In this study, the antitumor efficacy of radium-223, enzalutamide, and their combination was evaluated in a model of prostate cancer metastasis to bone. The combination treatment showed synergistic efficacy and enhanced antitumor effect in vitro and in vivo without compromising healthy bone integrity. These results support the ongoing phase 3 trial of radium-223 and enzalutamide combination therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Joan Carles, Teresa Alonso-Gordoa, Begona Mellado, Maria J. Mendez-Vidal, Sergio Vazquez, Aranzazu Gonzalez-del-Alba, Josep M. Piulats, Pablo Borrega, Enrique Gallardo, Rafael Morales-Barrera, Pilar Paredes, Oscar Reig, Carmen Garcias de Espana, Ricardo Collado, Teresa Bonfill, Cristina Suarez, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Garde
Summary: In this study of 52 patients with metastatic castration-resistant prostate cancer and asymptomatic bone metastases, treatment with Ra-223 was found to have longer radiographic progression-free survival (rPFS) and overall survival in patients with AR-V7(-) expression. Ra-223 demonstrated an acceptable safety profile for the treatment of these patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Ana Maria Garcia Vicente, Mariano Amo-Salas, Javier Cassinello Espinosa, Roberto Gomez Diaz, Angel Soriano Castrejon
Summary: The ChoPET-Rad study involving 82 patients with CRPC-BM demonstrated that end-treatment FCH PET/CT was associated with PFS and OS, while interim FCH PET/CT was a good predictor of biochemical progression. Therapeutic failure and progression in interim BS or FCH PET/CT were adverse factors for OS.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Ahmad Shariftabrizi, Shalin Kothari, Saby George, Kristopher Attwood, Ellis Levine, Dominick Lamonica
Summary: This study identifies bone scintigraphy as a potentially important biomarker for selecting prostate cancer patients with bone metastasis who will benefit most from Ra-223 treatment. Patients with lower baseline Bone Scan Index (BSI) levels are more likely to have better outcomes following treatment, while those with higher BSI levels have poorer survival rates.
Article
Oncology
Mari I. Suominen, Matias Knuuttila, Birgitta Sjoholm, Timothy Wilson, Esa Alhoniemi, Dominik Mumberg, Sanna-Maria Kakonen, Arne Scholz
Summary: Combination treatment with radium-223, abiraterone, and prednisone/prednisolone in prostate cancer patients with bone metastases increases the risk of non-pathological fractures. This study used a mouse model to investigate the mechanisms behind this outcome and found that the treatment induced temporary bone resorption and reduced new bone formation and osteoblasts, leading to an increased fracture risk.
Article
Oncology
Yoshiyuki Yamamoto, Yohei Okuda, Tomohiro Kanaki, Ryo Tanaka, Akira Nagahara, Yasutomo Nakai, Masashi Nakayama, Ken-ichi Kakimoto, Kazuo Nishimura
Summary: This study retrospectively analyzed patients treated with Ra-223 and found that a shorter PSA doubling time, a higher number of bone metastases, and a later treatment line before Ra-223 were associated with poor prognosis in mCRPC patients. These newly identified risk factors may help predict long-term overall survival after Ra-223 treatment.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Raniv D. Rojo, Joy Vanessa D. Perez, Jossana A. Damasco, Guoyu Yu, Song-Chang Lin, Francisco M. Heralde, Nora M. Novone, Elmer B. Santos, Sue-Hwa Lin, Marites P. Melancon
Summary: The combination of IRE with Ra-223 demonstrated effective inhibition of prostate cancer cell proliferation and reduced tumor recurrence rate by enhancing destruction of cancer cells adjacent to bone. This combination treatment also showed a significant reduction in cell viability in vitro and inhibited the proliferation of incompletely ablated tumor cells in vivo.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kazuhiro Kitajima, Masataka Igeta, Junpei Kuyama, Takashi Kawahara, Tsuyoshi Suga, Tomoaki Otani, Shigeyasu Sugawara, Yumiko Kono, Yukihisa Tamaki, Ayumi Seko-Nitta, Yoshinobu Ishiwata, Kimiteru Ito, Akira Toriihara, Shiro Watanabe, Makoto Hosono, Hideaki Miyake, Shingo Yamamoto, Mitsuhiro Narita, Takashi Daimon, Koichiro Yamakado
Summary: A novel nomogram for determining the suitability of radium-223 dichloride (Ra-223) treatment for metastatic castration-resistant prostate cancer (mCRPC) patients was developed. The nomogram showed good discrimination and could assist clinicians in making treatment decisions.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Maarten J. van der Doelen, Agnes Stockhaus, Yuanjun Ma, Niven Mehra, Jeffrey Yachnin, Winald R. Gerritsen, Sten Nilsson, Inge M. van Oort, Anders Ullen
Summary: The study showed that early treatment-induced changes in ALP after one radium-223 injection were associated with overall survival in metastatic CRPC patients.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Desiree Deandreis, Aline Maillard, Slimane Zerdoud, Claire Bournaud, Lavinia Vija, Christophe Sajous, Marie Terroir, Laurence Leenhardt, Martin Schlumberger, Isabelle Borget, Sophie Leboulleux
Summary: This study evaluated the efficacy of Radium-223 in treating bone metastases from RAIR thyroid cancer, showing stability in some patients after three and six injections, with no significant clinical benefits reported. The trial was stopped early due to lack of expected response of bone metastases to Radium-223.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Oncology
Anniina Hyvakka, Okko-Sakari Kaariainen, Tapio Utriainen, Eliisa Loyttyniemi, Kalle Mattila, Petri Reinikainen, Jorma Sormunen, Minna Jaaskelainen, Paivi Auvinen, Heikki Minn, Maria Sundvall
Summary: This retrospective multicenter study evaluated the efficacy and safety of radium-223 in the clinical practice of Finland for patients with metastatic castration-resistant prostate cancer (mCRPC). The results showed that radium-223 treatment was well tolerated and provided pain relief, while pain relief, ALP normalization, lower baseline PSA level, and PSA decrease during treatment were associated with better survival.
Article
Pharmacology & Pharmacy
Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma
Summary: This study assessed the cost effectiveness of radium-223 dichloride for Chinese patients with mCRPC. The results suggest that radium-223 may not be cost effective for patients with bone mCRPC from the perspective of the Chinese health system.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Kim van der Zande, Wim J. G. Oyen, Wilbert Zwart, Andries M. Bergman
Summary: Radium-223 dichloride ([Ra-223]RaCl2; Ra-223) is an alpha-emitting radiopharmaceutical used for the treatment of metastatic castration resistant prostate cancer (mCRPC) patients. While effective, there is a lack of predictive and prognostic tools for patient stratification and response evaluation. Further research is needed to explore potential biomarkers for predicting response to Ra-223 treatment.
Review
Biochemistry & Molecular Biology
Chirayu M. Patel, Thaddeus J. Wadas, Yusuke Shiozawa
Summary: Bone metastasis is a major cause of death in cancer patients, and current therapies are mainly palliative. However, systemic radiotherapy shows potential for improving overall survival in patients.
Article
Urology & Nephrology
Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, Daniel Koehler, Isabel Rauscher, Matthias Eiber, Fijs W. B. van Leeuwen, Pim van Leeuwen, Hilda de Barros, Henk van der Poel, Lars Budaeus, Thomas Steuber, Markus Graefen, Pierre Tennstedt, Matthias M. Heck, Thomas Horn, Tobias Maurer
Summary: This study evaluated the oncological outcomes of salvage PSMA-RGS in patients with recurrent oligometastatic prostate cancer and identified predictive preoperative factors for improved outcomes. The results showed that the 3-month and 2-year tumor survival rates were 32% and 58%, respectively. Preoperative PSA, number of PSMA-avid lesions, and localization of lesions were independent predictors of biochemical recurrence after PSMA-RGS.
Article
Radiology, Nuclear Medicine & Medical Imaging
Samaneh Azargoshasb, Imke Boekestijn, Meta Roestenberg, Gijs H. KleinJan, Jos A. van der Hage, Henk G. van der Poel, Daphne D. D. Rietbergen, Matthias N. van Oosterom, Fijs W. B. van Leeuwen
Summary: This study investigates the impact of signal-to-background ratios (SBR) on surgical performance using kinematics analysis. The results show that below SBR 1.5, task completion time, time spent in fluorescence-imaging mode, and total pathlength increase significantly, and handling errors become more frequent. The values of Dx and DM indicate that proficiency can only be achieved at SBR> 1.55.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Jean-Pierre Pouget, Mark Konijnenberg, Uta Eberlein, Gerhard Glatting, Pablo Minguez Gabina, Ken Herrmann, Soren Holm, Lidia Strigari, Fijs W. B. van Leeuwen, Michael Lassmann
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Computer Science, Interdisciplinary Applications
Anne Dirkson, Suzan Verberne, Gerard van Oortmerssen, Hans Gelderblom, Wessel Kraaij
Summary: Patients share coping strategies for illnesses in online support groups. Automatic extraction of these strategies from patient discussion groups has not been attempted before. This study introduces a new task that faces challenges such as complex entities, numerous labels, and relations between documents. The authors present an initial ontology for coping strategies and compare two computational solutions for this task. The evaluation results show limited performance, with multi-label classification outperforming named entity recognition with entity linking.
JOURNAL OF BIOMEDICAL INFORMATICS
(2023)
Letter
Pharmacology & Pharmacy
Mirjam de With, Jonathan Knikman, Jan H. M. Schellens, Hans Gelderblom, Annemieke Cats, Henk-Jan Guchelaar, Ron H. J. Mathijssen, Jesse J. Swen, Didier Meulendijks
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Emanuela Palmerini, John H. Healey, Nicholas M. Bernthal, Sebastian Bauer, Hendrik Schreuder, Andreas Leithner, Javier Martin-Broto, Francois Gouin, Julio Lopez-Bastida, Hans Gelderblom, Eric L. Staals, Florence Mercier, Petra Laeis, Xin Ye, Michiel van de Sande
Summary: This article describes the impact of Tenosynovial giant cell tumor (D-TGCT) on patient-reported outcomes (PROs) based on the Tenosynovial giant cell tumor Observational Platform Project (TOPP) registry. The study found that patients without active treatment strategy had lower pain levels and better quality of life at 1-year and 2-year follow-ups. On the other hand, patients receiving systemic treatment had higher pain levels when they changed treatment strategies. These findings highlight the significant impact of treatment strategies on patient quality of life.
Article
Oncology
Hans Gelderblom, Robin L. Jones, Jean-Yves Blay, Suzanne George, Margaret von Mehren, John R. Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, Cesar Sanchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, Cesar Serrano, Neeta Somaiah, Ping Chi, Brooke Harrow, Claus Becker, William Reichmann, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michael C. Heinrich, INTRIGUE Investigators
Summary: In the INTRIGUE trial, there was no significant difference in progression-free survival between ripretinib and sunitinib for advanced gastrointestinal stromal tumour (GIST) patients. The study compared the impact of these treatments on health-related quality of life (HRQoL) and found that patients receiving ripretinib had better HRQoL during the dosing period compared to patients receiving sunitinib.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Philip Heesen, Andreas Ranft, Vivek Bhadri, Benedicte Brichard, Stephane Collaud, Sona Cyprova, Hans Eich, Torben Ek, Hans Gelderblom, Jendrik Hardes, Lianne Haveman, Susanne Jabar, Wolfgang Hartmann, Dimosthenis Andreou, Peter Hauser, Josephine Kersting, Heribert Juergens, Jukka Kanerva, Thomas Kuehne, Anna Raciborska, Jelena Rascon, Arne Streitbuerger, Beate Timmermann, Yasmin Uhlenbruch, Uta Dirksen
Summary: This study analyzed the association between local therapy and event-free survival (EFS), overall survival (OS), and local recurrence (LR) in patients with Ewing sarcoma. The results showed that in certain situations, combination therapy with radiotherapy and surgery can improve the prognosis of patients. This provides important evidence for the personalized treatment of Ewing sarcoma.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
William D. Tap, Maitreyi G. Sharma, Marc Vallee, Bryan D. Smith, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michiel van de Sande, R. Lor Randall, Nicholas M. Bernthal, Hans Gelderblom
Summary: TGCT is a rare neoplasm caused by upregulation of the CSF1 gene. Vimseltinib, an oral tyrosine kinase inhibitor, is being tested in the Phase III MOTION trial for its efficacy and safety in TGCT patients who are not suitable for surgery. Participants will receive vimseltinib or placebo in Part 1, followed by open-label vimseltinib treatment in Part 2.
Article
Medicine, General & Internal
Adrian Sacher, Patricia LoRusso, Manish R. Patel, Wilson H. Miller, Elena Garralda, Martin D. Forster, Armando Santoro, Alejandro Falcon, Tae Won Kim, Luis Paz-Ares, Samantha Bowyer, Maria de Miguel, Sae-Won Han, Matthew G. Krebs, Jong-Seok Lee, Michael L. Cheng, Kathryn Arbour, Erminia Massarelli, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer-Joo, Julie Chang, Neekesh V. Dharia, Jennifer L. Schutzman, Jayesh Desai
Summary: Divarasib, a KRAS G12C inhibitor, has shown promising therapeutic effects with minimal adverse events in patients with tumors harboring the KRAS G12C mutation.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Astrid Lipplaa, Willem H. Schreuder, Sarina E. C. Pichardo, Hans Gelderblom
Summary: This study aimed to determine the efficacy of denosumab in patients with giant cell rich tumors of bone (GCRTB) that have recurred or require morbid surgery. Due to low patient accrual, the study was prematurely stopped and the results did not support the use of denosumab for this indication.
Editorial Material
Pharmacology & Pharmacy
Sofia L. J. Peeters, Maarten J. Deenen, Anna M. J. Thijs, Emma C. Hulshof, Ron H. J. Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J. Swen
Review
Radiology, Nuclear Medicine & Medical Imaging
Matthias N. van Oosterom, Samaneh Azargoshasb, Leon J. Slof, Fijs W. B. van Leeuwen
Summary: With the increasing use of robotic platforms in laparoscopic surgery, radioguidance has the potential to play a crucial role in improving surgical precision. Although there are challenges and limitations, recent developments have shown progress in integrating radioguidance with robotic laparoscopic surgery.
CLINICAL AND TRANSLATIONAL IMAGING
(2023)
Article
Oncology
Emanuela Palmerini, John H. Healey, Nicholas M. Bernthal, Sebastian Bauer, Hendrik Schreuder, Andreas Leithner, Javier Martin-Broto, Francois Gouin, Julio Lopez-Bastida, Hans Gelderblom, Eric L. Staals, Florence Mercier, Petra Laeis, Xin Ye, Michiel van de Sande
Summary: This study investigated the impact of diffuse-type Tenosynovial giant cell tumor (D-TGCT) on treatment strategies and quality of life for patients. The results showed that patients who switched to an active treatment strategy had higher scores for pain and interference, while patients who remained off-treatment had lower scores at the 2-year follow-up. These findings are important for guiding the treatment and management of D-TGCT.
Article
Surgery
Matthias N. van Oosterom, Sven van Leeuwen, Elio Mazzone, Paolo Dell'Oglio, Tessa Buckle, Florian van Beurden, Michael Boonekamp, Huybert van de Stadt, Kevin Bauwens, Herve Simon, Pim J. van Leeuwen, Henk G. van der Poel, Fijs W. B. van Leeuwen
Summary: This study engineered a 'click-on' fluorescence detector that transforms standard robotic instruments into molecular sensing devices, enabling the detection of near-infrared fluorescence in a white-light setting. The detector showed promising performance in detecting blood vessels, assessing vascularization, and localizing lymph nodes during robotic surgery in pigs and human specimen evaluation.
JOURNAL OF ROBOTIC SURGERY
(2023)
